MALIN CORP PLC (MLC.I) Stock Price & Overview
DUB:MLC • IE00BVGC3741
Current stock price
The current stock price of MLC.I is 7.6 EUR. Today MLC.I is down by 0%. In the past month the price decreased by -5%. In the past year, price increased by 26.67%.
MLC.I Key Statistics
- Market Cap
- 32.908M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
MLC.I Stock Performance
MLC.I Stock Chart
MLC.I Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MLC.I. When comparing the yearly performance of all stocks, MLC.I turns out to be only a medium performer in the overall market: it outperformed 63.01% of all stocks.
MLC.I Earnings
MLC.I Forecast & Estimates
5 analysts have analysed MLC.I and the average price target is 15.81 EUR. This implies a price increase of 108.03% is expected in the next year compared to the current price of 7.6.
MLC.I Groups
Sector & Classification
MLC.I Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MLC.I Ownership
MLC.I Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 56S1 | SARTORIUS STEDIM BIOTECH | 31.74 | 16.259B | ||
| SRT3 | SARTORIUS AG-VORZUG | 36.01 | 16.099B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 30.51 | 15.631B | ||
| SRT | SARTORIUS AG | 28.33 | 12.685B | ||
| QIA | QIAGEN N.V. | 16 | 7.292B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.43 | 2.045B | ||
| EVT | EVOTEC SE | N/A | 1.529B | ||
| GXI | GERRESHEIMER AG | 6.75 | 637.954M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 13.04 | 230.527M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 180M |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Dublin Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About MLC.I
Company Profile
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 2 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, WaveBreak, KNOW Bio, and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. KNOW Bio is a life science company engaged in the fields of nitric oxide and precision light therapy. WaveBreak Therapeutics company focuses on the development of medicines for the treatment of protein-misfolding diseases including Alzheimer's and Parkinson's. Artizan is a biotechnology company.
Company Info
IPO: 2015-03-25
MALIN CORP PLC
The Lennox Building, 50 Richmond Street South
DUBLIN DUBLIN IE
Employees: 2
Phone: 353019053531
MALIN CORP PLC / MLC.I FAQ
What does MALIN CORP PLC do?
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 2 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, WaveBreak, KNOW Bio, and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. KNOW Bio is a life science company engaged in the fields of nitric oxide and precision light therapy. WaveBreak Therapeutics company focuses on the development of medicines for the treatment of protein-misfolding diseases including Alzheimer's and Parkinson's. Artizan is a biotechnology company.
What is the stock price of MALIN CORP PLC today?
The current stock price of MLC.I is 7.6 EUR.
Does MLC stock pay dividends?
MLC.I does not pay a dividend.
What is the ChartMill technical and fundamental rating of MLC stock?
MLC.I has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is MLC.I stock listed?
MLC.I stock is listed on the Euronext Dublin exchange.
What is the ownership structure of MALIN CORP PLC (MLC.I)?
You can find the ownership structure of MALIN CORP PLC (MLC.I) on the Ownership tab.